Description
Background:
Ofatumumab is a fully human monoclonal antibody to CD20, which appears to provide rapid B-cell depletion.Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the European Union and other regions.Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL)
Intended Use:
For Estimation of Ofatumumab (ARZERRA) in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!